CS
ANAC

Credit Suisse’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Credit Suisse’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-120,563
Closed -$6.44M – 4524
2016
Q1 		$6.44M Buy
120,563
+32,220
+36% +$2.38M 0.01% 1372
2015
Q4 		$9.98M Sell
88,343
-21,280
-19% -$2.34M 0.01% 1145
2015
Q3 		$12.9M Sell
109,623
-75,060
-41% -$9.8M 0.02% 975
2015
Q2 		$14.3M Buy
184,683
+27,381
+17% +$1.8M 0.01% 1019
2015
Q1 		$9.1M Sell
157,302
-21,733
-12% -$923K 0.01% 1258
2014
Q4 		$5.77M Buy
179,035
+27,350
+18% +$821K 0.01% 1648
2014
Q3 		$3.71M Buy
151,685
+50,584
+50% +$1.03M ﹤0.01% 1990
2014
Q2 		$1.79M Buy
101,101
+5,073
+5% +$81.7K ﹤0.01% 2819
2014
Q1 		$1.92M Buy
96,028
+5,646
+6% +$109K ﹤0.01% 2535
2013
Q4 		$1.52M Buy
90,382
+3,649
+4% +$50.5K ﹤0.01% 2919
2013
Q3 		$921K Buy
86,733
+52,226
+151% +$457K ﹤0.01% 3032
2013
Q2 		$193K Buy
+34,507
New +$209K ﹤0.01% 3872

Other funds holding ANAC

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Credit Suisse's ANAC Position: Q2 2016 in Review

Credit Suisse sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 120,563 shares — an estimated $6.44M sold.

Credit Suisse first reported a position in ANAC in Q2 2013 and held it in 12 quarters. The position peaked at $14.3M in Q2 2015. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

  • Credit Suisse reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • Credit Suisse sold 120,563 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $6.44M.
  • Credit Suisse first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 12 quarters.
  • Credit Suisse's ANACOR PHARMACEUTICALS INC COM position peaked at $14.3M in Q2 2015.
  • 2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on Credit Suisse's 13F filing for Q2 2016, filed 11 Aug 2016.